📊 CRBU Key Takeaways
Investment Thesis
Caribou Biosciences is a pre-revenue clinical-stage biotech company with severe operating losses and massive cash burn that far exceeds revenue generation. With only $12.4M in cash against $111M annual operating cash burn, the company faces critical liquidity constraints and will require significant capital raises or major clinical success to avoid financial distress within 12 months.
CRBU Strengths
- Strong balance sheet with $122.2M stockholders equity provides substantial capital base
- Excellent liquidity position with 5.71x current ratio indicating near-term payment capability
- Zero long-term debt eliminates refinancing risk and interest burden
- Revenue growth of 11.7% YoY shows emerging commercial activity from R&D programs
CRBU Risks
- Catastrophic cash burn of $111M annually against only $12.4M cash reserves indicates 1.3 months of runway at current burn rate
- Operating losses of $148.3M on $11.2M revenue demonstrates completely unprofitable operations with losses 1,329% of revenue
- Pre-commercial biotech model creates absolute dependence on clinical trial success and future funding; single negative trial result could be fatal
- Negative free cash flow of $112.4M combined with minimal revenue makes the company entirely dependent on capital markets for survival
- High insider trading activity (14 Form 4 filings in 90 days) may indicate uncertainty or management exit timing concerns
Key Metrics to Watch
- Cash position and runway until next financing required
- Clinical trial progress and regulatory milestones for lead programs
- Monthly cash burn rate and achievement of operational cost reduction targets
- Ability to secure funding and terms of future capital raises
- Revenue growth trajectory from commercialization efforts
CRBU Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.71x current ratio provides a solid financial cushion.
CRBU Profitability Ratios
CRBU vs Healthcare Sector
How Caribou Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CRBU Balance Sheet & Liquidity
CRBU 5-Year Financial Trend
5-Year Trend Summary: Caribou Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 10% decline. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
CRBU Growth Metrics (YoY)
CRBU Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.0M | -$27.5M | $-0.30 |
| Q2 2025 | $2.7M | -$37.7M | $-0.42 |
| Q1 2025 | $2.4M | -$40.0M | $-0.43 |
| Q3 2024 | $2.0M | -$10.0M | $-0.12 |
| Q2 2024 | $3.5M | -$28.0M | $-0.42 |
| Q1 2024 | $2.4M | -$28.0M | $-0.46 |
| Q3 2023 | $3.3M | -$10.0M | $-0.12 |
| Q2 2023 | $3.8M | -$19.1M | $-0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CRBU Capital Allocation
CRBU SEC Filings
Access official SEC EDGAR filings for Caribou Biosciences, Inc. (CIK: 0001619856)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRBU
What is the AI rating for CRBU?
Caribou Biosciences, Inc. (CRBU) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRBU's key strengths?
Strong balance sheet with $122.2M stockholders equity provides substantial capital base. Excellent liquidity position with 5.71x current ratio indicating near-term payment capability.
What are the risks of investing in CRBU?
Catastrophic cash burn of $111M annually against only $12.4M cash reserves indicates 1.3 months of runway at current burn rate. Operating losses of $148.3M on $11.2M revenue demonstrates completely unprofitable operations with losses 1,329% of revenue.
What is CRBU's revenue and growth?
Caribou Biosciences, Inc. reported revenue of $11.2M.
Does CRBU pay dividends?
Caribou Biosciences, Inc. does not currently pay dividends.
Where can I find CRBU SEC filings?
Official SEC filings for Caribou Biosciences, Inc. (CIK: 0001619856) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRBU's EPS?
Caribou Biosciences, Inc. has a diluted EPS of $-1.59.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.